Haemonetics
301 hedge funds and large institutions have $2.5B invested in Haemonetics in 2025 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 96 increasing their positions, 118 reducing their positions, and 52 closing their positions.
58% more call options, than puts
Call options by funds: $31.7M | Put options by funds: $20.1M
1% more funds holding
Funds holding: 298 → 301 (+3)
10% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 52
6.34% less ownership
Funds ownership: 112.87% → 106.52% (-6.3%)
19% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 118
38% less capital invested
Capital invested by funds: $4.05B → $2.5B (-$1.55B)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$104M |
| 2 |
Millennium Management
New York
|
+$45.5M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$36.1M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$29.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$113M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$85M |
| 3 |
SCM
SG Capital Management
Chicago,
Illinois
|
-$56.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$43.8M |
| 5 |
Neuberger Berman Group
New York
|
-$37.6M |
HAE Hedge Fund Activity: Q3 2025 in Review
301 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2025, worth a combined $2.5B — down 38% from $4.05B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new HAE positions and 52 closed out — a net gain of 5 holders — while 96 added to existing stakes and 118 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $104M. The largest seller was Wellington Management Group, cutting an estimated $113M.
- 301 institutional investors held Haemonetics (HAE) as of Q3 2025, up from 298 in Q2 2025.
- Funds reported $2.5B of Haemonetics stock for Q3 2025, down 38% quarter-over-quarter.
- 57 funds opened new Haemonetics positions in Q3 2025 and 52 closed out, a net change of +5 holders.
- The largest Haemonetics buyer in Q3 2025 was AQR Capital Management, an estimated $104M added.
- The largest Haemonetics seller in Q3 2025 was Wellington Management Group, an estimated $113M sold.
Based on aggregated 13F filings for Q3 2025.